Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hamsa Biopharma
Lund, Skåne, Sweden
- Ownership
- Private
- Employees
- ~166
- Development stage
- Other
01
Overview
Imlifidase (Idefirix) has conditional approval in the EU for desensitization in highly sensitized kidney transplant patients, with ongoing global Phase 3 trials and development across multiple rare immunologic and autoimmune indications[5][4][1]. Additional preclinical and clinical programs target expansion into gene therapy and other autoimmune areas with novel next-generation enzymes[2][4].
- Therapeutic areas
- NephrologyImmunologyNeurologyRare Diseases
- Modalities
- EnzymeBiologic
- Industry
- Biotech
02
Partnerships
Sarepta Therapeutics (gene therapy/DMD)Genethon (gene therapy/Crigler-Najjar syndrome)[2]
Beyond the preview
Go deeper on Hamsa Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hamsa Biopharma.